Charles River Laboratories (CRL) Tops Q4 EPS by 6c; Guides FY16 EPS Above Consensus Midpoint
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.00, $0.06 better than the analyst estimate of $0.94. Revenue for the quarter came in at $353.9 million versus the consensus estimate of $349.2 million.
GUIDANCE:
2016 GUIDANCE EXCLUDING WIL RESEARCH | |||
(from continuing operations) | |||
| Revenue growth, reported | 8% - 10% | ||
| Negative impact of foreign exchange | (~1%) | ||
| Revenue growth, constant currency | 9% - 11% |
Charles River Laboratories sees FY2016 EPS of $4.07-$4.17, versus the consensus of $4.16.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.